1	Cardiac Inflammation after COVID-19 mRNA Vaccines:
2	A Global Pharmacovigilance Analysis
3	Brief title: Cardiac Inflammation after COVID-19 Vaccines
4	
5	Laurent Chouchana PharmD, PhD ¹ * [¶] , Alice Blet MD, PhD ^{2,3,4} *, Mohammad Al-Khalaf PhD ^{2,}
6	Tahir S. Kafil, MD ² , Girish Nair, MD ² , James Robblee, MD ² , Milou-Daniel Drici, MD, PhD ⁵ ,
7	Marie-Blanche Valnet-Rabier, PharmD, PhD ^{6¶} , Joëlle Micallef, MD, PhD ^{7¶} , Francesco Salvo,
8	MD, PhD ^{8,9¶} , Jean-Marc Treluyer, MD, PhD 1,10¶ and Peter P. Liu MD 2
9	
10	¹ Regional Center of Pharmacovigilance, Department of Pharmacology, Cochin Hospital, AP-HP.Centre –
11	Université de Paris, Paris, France.
12	² University of Ottawa Heart Institute, Departments of Medicine and Cellular & Molecular Medicine (P.P.L.,
13	M.A.K), University of Ottawa, Ontario, Canada.
14	³ Department of Anesthesiology, Critical Care and Burn Center, Lariboisière - Saint-Louis Hospitals, DMU
15	Parabol, AP–HP Nord, University of Paris, France.
16	⁴ Inserm UMR-S 942, Cardiovascular Markers in Stress Conditions (MASCOT), University of Paris, France.
17	⁵ Regional Center of Pharmacovigilance, Department of Pharmacology, Nice University Hospital, Nice, France
18	⁶ Regional Center of Pharmacovigilance, Department of Pharmacology, Besançon University Hospital, Besançon,
19	France
20	⁷ UMR 1106, Institute of Neurosciences System, Aix-Marseille University, Inserm, Marseille, France. Regional
21	center of Pharmacovigilance, Department of Clinical Pharmacology and Pharmacovigilance, University Hospitals
22	of Marseille, Marseille, France.
23	⁸ Univ. Bordeaux, INSERM, BPH, U1219, F-33000 Bordeaux, France
24	⁹ CHU de Bordeaux, Pôle de Santé Publique, Service de Pharmacologie médicale, Centre Régional de
25	Pharmacovigilance, Bordeaux ¹⁰ University of Paris, Paris, France.
26	
27	* LC and AB share first position authorship.
28	[¶] Laurent Chouchana, Milou-Daniel Drici, Marie-Blanche Valnet-Rabier, Joëlle Micallef, Francesco Salvo and
29	Jean-Marc Treluyer are members of the French Pharmacovigilance Network.
30	
31	Address for correspondence: Dr. Peter Liu
32	peter.liu@utoronto.ca OR pliu@ottawaheart.ca
33	Phone: +1 613 696 7000 x 19544 / Fax: +1 613 696 7138
34 25	University of Ottawa Heart Institute
35 36	40 Ruskin Street, Ottawa, ON K1Y 4W7, Canada
36	

37	Sources of funding: This work	is supported in part by rese	earch grants from the Canadia	n
38	Institutes of Health Research, He	art & Stroke Foundation of	Canada, Genome Canada, an	d
39	University of Ottawa of Heart Instit	tute.		
40				
41	Disclosures: none			
42				
43	Total word count: 6910	Number of figures: 5	Number of tables: 2	
44				
45				
46				
47				

48 ABSTRACT

49 Background

50 To counter the COVID-19 pandemic, mRNA vaccines, namely tozinameran and 51 elasomeran, have been authorized in several countries. These next generation vaccines have 52 shown high efficacy against COVID-19 and demonstrated a favorable safety profile. As 53 widespread vaccinations efforts are taking place, incidents of myocarditis and pericarditis cases 54 following vaccination have been reported. This safety signal has been recently confirmed by the 55 European Medicine Agency and the U.S. Food and Drug Administration.

56 This study aimed to investigate and analyze this safety signal using a dual 57 pharmacovigilance database analysis.

58 Methods

This is as an observational study of reports of inflammatory heart reactions associated with mRNA COVID-19 vaccines reported in the World Health Organization's global individual case safety report database (up to June 30th 2021), and in the U.S. Vaccine Adverse Event Reporting System (VAERS, up to May 21st 2021). Cases were described, and disproportionality analyses using reporting odds-ratios (ROR) and their 95% confidence interval (95%CI) were performed to assess relative risk of reporting according to patient sex and age.

65 *Results*

At a global scale, the inflammatory heart reactions most frequently reported were myocarditis (1241, 55%) and pericarditis (851, 37%), the majority requiring hospitalization (n=796 (64%)). Overall, patients were young (median age 33 [21-54] years). The main age group was 18-29 years old (704, 31%), and mostly males (1555, 68%). Pericarditis onset was delayed compared to myocarditis with a median time to onset of 8 [3-21] *vs.* 3 [2-6] days, respectively (p=0.001). Regarding myocarditis, an important disproportionate reporting in males (ROR, 9.4

[8.3-10.6]) as well as in adolescents (ROR, 22.3 [19.2-25.9]) and 18-29 years old (ROR, 6.6 [5.97.5]) compared to older patients were observed.

74 *Conclusions*

The inflammatory heart reactions, namely myocarditis and pericarditis, have been reported world-wide shortly following COVID-19 mRNA vaccination. An important disproportionate reporting among adolescents and young adults, particularly in males, was observed especially for myocarditis. Guidelines must take this specific risk into account and to optimize vaccination protocols according to sex and age. While the substantial benefits of COVID-19 vaccination still prevail over risks, clinicians and the public should be aware of these reactions and seek appropriate medical attention.

82

83 Key words

mRNA vaccines, myocarditis, pericarditis, adverse drug reactions, pharmacovigilance, COVID19 vaccines

87 ABBREVIATION LIST

CDC	Centers for Disease Control and Prevention
95%CI	Confidence Interval 95%
COVID-19	coronavirus disease
FDA	U.S. Food and Drug Administration
IQR	interquartile range
MedDRA	Medical Dictionary for Regulatory Activities
mRNA	messenger RNA
OR	Odds Ratio
ROR	Reporting Odds Ratio
VAERS	Vaccine Adverse Event Reporting System
WHO	World Health Organization

90 Introduction

91 Myocarditis and pericarditis are inflammatory heart conditions that occur in the setting of 92 excessive host immune response to antigenic stimuli, and have diverse outcomes ranging from mild to severe.¹ They usually occur after viral infections or other stimuli that induce immune 93 system activation.² Recently, viral myocarditis has been widely reported after SARS-CoV-2 94 infection and subsequent development of coronavirus disease (COVID-19).^{3,4} In some instances. 95 96 these inflammatory reactions have been associated with some drug exposure, such anticancer agents, clozapine or vaccines.^{5–7} A descriptive analysis of drug associated myopericarditis 97 98 spontaneous reports in the United States (1990-2018) identified that about 0.1% of the cases were related to vaccines.⁸ To date, inflammatory cardiac reactions following vaccination have 99 been mostly reported with live-virus vaccines, such as the smallpox vaccine, ^{6,9,10} and inactivated 100 influenza vaccines,¹¹ Cases reports of myocarditis/pericarditis secondary to next-generation 101 vaccine platforms, used to prevent COVID-19, have been reported.^{12–17} 102

103 Vaccination is critical to contain the SARS-CoV-2 pandemic. Messenger RNA (mRNA) 104 vaccines, which have been produced experimentally during the Zika virus outbreak, represent a 105 new generation of vaccines that can be rapidly responsive to emerging viruses, such as SARS-CoV-2.¹⁸ Pivotal phase 3 randomized clinical trials were conducted on 71,265 volunteers, 106 including 35,654 who were exposed to the active mRNA vaccines.^{19,20} Up to July 2021, 107 108 tozinameran (BNT162b2 mRNA, Pfizer-BioNTech) and elasomeran (mRNA 1273, Moderna) 109 have been distributed in 104 and 49 countries worldwide, respectively, and more than 341 million doses have been administered in the U.S.²¹ While these vaccines appear to have a particularly 110 111 good safety profile, special attention must be paid to potential adverse effects due to their 112 novelty. Rare but severe adverse drug reactions have been highlighted in clinical trials and thereafter reported after COVID-19 mRNA vaccination, such as anaphylaxis or Bell's palsy.²²⁻²⁴ 113

Recently, a growing signal concerning inflammatory heart reactions, which has not been pointed out during clinical trials, has emerged in several regions of the world, including Israel, Europa and the U.S., with early coverage in the press.^{25–27} A small case series in members of the U.S. Military suggested an incidence below one over 100,000 doses administered.¹⁴ Preliminary analysis by national authorities led to confirm this safety signal and a probable causal relationship in Europe and in the U.S.^{28,29}

120 In this study, we aim to document the inflammatory heart reactions reported after 121 COVID-19 mRNA vaccination and further analyze this safety signal using a dual 122 pharmacovigilance database analysis based on the World Health Organization's (WHO) global 123 Individual Case Safety Report database (VigiBase) and the U.S. Vaccine Adverse Event 124 Reporting System (VAERS). The aims of the study are: 1) to describe these cases and their 125 relevant clinical features, and 2) to perform disproportionality analyses to evaluate a potential 126 association of inflammatory heart reactions reporting after mRNA COVID-19 vaccines with 127 patient's sex and age.

- 128
- 129
- 130
- 131 Methods
- 132 Study Design

This is a retrospective observational study of spontaneous reports of inflammatory heart
reactions associated with mRNA COVID-19 vaccines, collected from VigiBase and the VAERS.

136 Data Source

137 VigiBase (https://www.who-umc.org/vigibase/vigibase/) is the unique WHO global database of individual case safety reports (ICSRs).³⁰ This database is maintained, deduplicated 138 139 and deidentified by Uppsala Monitoring Centre (Uppsala, Sweden). VigiBase is the world's 140 largest pharmacovigilance database, with over 23 million reports of suspected adverse drug 141 reactions gathered from national pharmacovigilance systems and continuously updated. More 142 than 130 countries, over five continents submit spontaneous safety report in this database. 143 Information concerning the reporter, the patient, the suspected and concomitant drugs, the 144 suspected adverse drug reactions and their seriousness, are reported for each case. Reactions are 145 coded using the hierarchical Medical Dictionary for Regulatory Activities (MedDRA) 146 (https://www.meddra.org/).

147 VAERS (www.vaers.hhs.gov) is the national pharmacovigilance database to monitor the safety of U.S.-licensed vaccines.^{31,32} It is run by the Centers for Disease Control and Prevention 148 149 (CDC) and the U.S. Food and Drug Administration (FDA). VAERS is a spontaneous, passive, 150 reporting system. Health-care professionals, vaccine manufacturers, and consumers (patients, 151 parents, and caregivers) can submit reports of suspected adverse drug reactions to VAERS. They 152 include a short narrative with clinical and biological features on the patient medical history, the 153 reaction and its outcome. This short narrative allows data extraction to deeper describe the 154 reports. U.S. reports from VAERS are transmitted to VigiBase on a regular basis.

155

156 Ethics

This study has obtained ethics approval from the Cochin university Hospital institutional review board (number AAA-2021-08039) in conformity with the French laws and regulations.³³ All of the data used for analysis were de-identified, and only aggregate data are reported.

161 Data Extraction and Analysis

Reports including a COVID-19 mRNA vaccine (tozinameran or elasomeran) as the suspected drug in the adverse reaction have been extracted from both databases. From that, cases of inflammatory heart reactions, i.e. myocarditis, myopericarditis, pericarditis, and pleuropericarditis, were retrieved using the *ad-hoc* high-level terms from MedDRA, "non infectious myocarditis" and "non infectious pericarditis", coded as reactions. Cases included in this study were registered up to May 21st and June 30th 2021, in VAERS and in VigiBase, respectively.

In VigiBase, for each report of interest, the following data were extracted or assessed: demographic features, continent of reporting, type of reporter, month of reporting, patient sex, patient age, time to reaction onset, seriousness, reaction outcome and type of heart inflammatory reaction Serious cases were defined, according to the WHO, as the occurrence of death, lifethreatening adverse event, inpatient hospitalisation or prolongation of an existing hospitalisation, significant disability or requirement of intervention to prevent any of these.

In VAERS, for each report of interest, the following data were extracted or assessed: vaccine type, type of heart inflammatory reaction, patient age, sex, COVID-19 prior to vaccination, reaction occurrence after the 1st or 2nd dose of vaccine, onset of the symptoms, type of symptoms, biological and radiological exams, complications, treatment, and hospitalization. Duplicates in VAERS were removed when identified from the short narrative.

180

181 Disproportionality analysis

182 Disproportionality analyses, also called case – non-case studies are similar to case – control 183 studies but for purpose of pharmacovigilance studies. These studies are nested in a database of 184 spontaneous reports to assess possible disproportionality in reporting. Disproportionality analysis

185 compares the proportion of a specific adverse drug reaction reported in a specific group (e.g. drug 186 exposure, patient age, patient sex) with the proportion of the same adverse drug reaction for a control group.^{34–36} This statistical approach has shown its value to assess relative risks of adverse 187 drug reaction, that are correlated in most cases with results from meta-analyses of clinical trials.³⁷ 188 189 To assess an association between inflammatory heart reactions after mRNA vaccines and patient 190 age or sex, we performed a disproportionality analysis among different patient groups. 191 Characteristics of interest are patient sex and age groups, specially 12-17 years, 18-29 years and 192 over 30 years, as reported by safety signals of concern. Cases are reports concerning a specific 193 patient group and that include the terms myocarditis, pericarditis or pleuropericarditis as reactions 194 after a COVID-19 mRNA vaccine. Non-cases are reports concerning a specific patient group and 195 that include all other reactions to a COVID-19 mRNA vaccine. Therefore, our analyses assessed 196 a potential difference of reporting of inflammatory heart reactions secondary to COVID-19 197 mRNA vaccines in male compared to female and in 12-17 years or 18-29 years old patients 198 compared to patients over 30 years old. Thereafter, sensitivity analyses were performed, 199 restricted to serious reports only, and to reports originating from a healthcare professional.

200

201 Statistical analysis

Descriptive analysis was performed on the cases retrieved from the two databases. Quantitative variables were expressed as median \pm interquartile range (IQR) and compared using nonparametric analysis. Qualitative variables were expressed in number and percentages. Time to reaction onset was analyzed using a survival Mantel-Cox model.

Disproportionality in reporting between groups is expressed using reporting odds ratio (ROR) and its 95% confidence interval (95% CI). ROR is a ratio similar in concept to the odds ratio in case – control studies and corresponds to the exposure odds among reported cases of interest over

the exposure odds among reported non-cases. ROR (95% CI) were calculated as $\frac{ad}{bc} \left(e^{\pm 1.96 \sqrt{\left(\frac{1}{a} + \frac{1}{b} + \frac{1}{c} + \frac{1}{d}\right)}} \right)$, where *a* is the number of cases reported with COVID-19 mRNA vaccines in a specific patient group, *b* is the number of non-cases (i.e., all other adverse drug reactions) reported with COVID-19 mRNA vaccines in a specific patient group, *c* is the number of cases reported with COVID-19 mRNA vaccines in a control group and *d* is the number of noncases reported with COVID-19 mRNA vaccines in a control group.

- 215
- 216
- 217 **Results**

218 Demographics and characteristics of cases from the worldwide VigiBase

219 As of the end of June 2021, of a total of 26,258,646 reports registered in VigiBase, 220 716,576 reports were related to a COVID-19 mRNA vaccine as a suspected drug, including 221 495,493 with tozinameran and 221,368 with elasomeran (including 285 with both vaccines). 222 Among them, 2277 cases of inflammatory heart reactions (31.8 per 10,000 of COVID-19 mRNA 223 vaccine reports) were retrieved in the worldwide VigiBase. Cases were largely reported from 224 North America (63.4%) and Europa (35.0%). Of the cases, 1655 (72.7%) were reported with 225 tozinameran and 622 (27.3%) with elasomeran (**Table 1**). The inflammatory heart reactions most 226 commonly reported were myocarditis (1241, 54.5%) and pericarditis (851, 37.4%). Patients were of the younger age bracket (median age 33 [21-54]) mostly from the group between 18-29 year-227 228 old (704, 30.9%), more commonly males (1555 (68.3%). Patient distribution was different 229 according to age and sex (p<0.0001) for both myocarditis and pericarditis (Figure 1). 230 Specifically, most of myocarditis cases have been reported in 12-17 and 18-29 years old males. 231 Myocarditis cases originating from the U.S. were mainly reported after May 2021, although 232 reactions occur alongside with vaccination achievements (Figure 2A and suppl. figure 1). 233 Overall, the median time to onset was 3 [2-14] days after vaccine injection. Pericarditis onset was 234 delayed compared to myocarditis with a median time to onset of 8 [3-21] vs. 3 [2-6] days, 235 respectively (p=0.001, Figure 3A). Drug other than COVID-19 mRNA vaccines were suspected 236 in the cardiac reaction onset in 200 (8.7%) patients. Overall, most of the myocarditis and 237 pericarditis reported cases required hospitalization (1015 (81.8%) and 492 (57.8%), respectively), 238 and 219 (21.5%) and 101 (20.5%) were life threatening, respectively. In 22 patients, including 15 239 (1.2%) myocarditis cases (median age 60 [56-78] years old), 5 pericarditis cases (median age 71 240 [67-77] years old) and 2 myopericarditis cases (age 55 and 83), the cardiac inflammatory reaction 241 had a fatal outcome. Among these fatal cases, the vaccine was the only suspected drug in all 242 except one case (an anti-PDL1, atezolizumab, as other suspected drug).

243

244 Disproportionality analysis

245 Compared to females, vaccination by COVID-19 mRNA vaccines in males was 246 associated with an increased risk of myocarditis and pericarditis reporting with an ROR (95% CI) 247 of 9.4 (8.3-10.6) and 3.7 (3.2-4.2), respectively (Figure 4A and B). Analysis according to age 248 group showed a marked disproportionate reporting of myocarditis after COVID-19 mRNA 249 vaccines in 12-17 years old (ROR 22.3 [19.2-25.9]) and 18-29 years old (ROR 6.6 [5.9-7.5]) 250 recipients compared with recipients over 30 years old. Specifically, this increased reporting was 251 more marked in males than in females, among all age groups (Figure 4A). Regarding 252 pericarditis, a disproportionate reporting in males among all age groups, compared to females 253 was observed (Figure 4B). Younger males belonging to 12-17 and 18-29 years old groups were 254 also more prone to pericarditis reporting after COVID-19 mRNA vaccines compared to over 30 255 years old group. This finding not being true in females in whom no disproportionality in 256 pericarditis reporting was observed according to age. Further sensitivity analyses restricted to 257 serious reports and to reports originating form healthcare professionals identified consistent 258 results (**Suppl tables S2, S3, S4 and S5**).

259

260 Demographic and characteristics of cases from the U.S. VAERS

261 A total of 279 cases of inflammatory cardiac reaction with COVID-19 mRNA vaccines 262 were reported in VAERS during the observed period. Of them, 157 (56%) myocarditis and 122 263 (44%) pericarditis cases were reported (Table 2, Suppl. Table 1). Patients were young belonging 264 to the 18-39 age group (142, 51%), more commonly males (182, 65%). Adverse reactions occurred after the 1st dose for 52 (19%), or after the 2nd dose for 87 (31%) and unspecified for 265 266 140 (50%) of reported cases. COVID-19 disease prior to vaccination was reported for 18 (6%) 267 patients. There was no concomitant COVID-19 reported. Although the median time to onset was 268 similar for myocarditis and pericarditis, it tends to be longer for pericarditis (3 [2-4] days vs. 3 [2-269 9] days, respectively). Main symptoms are reported for myocarditis and pericarditis (respectively) 270 Figure 3B and C), with chest pain being most common. As illustrated in Figure 5, most cases of 271 myocarditis experienced systemic reactogenicity signs (myalgia, fatigue, lymphedema on 272 axillary, sweats and chills, fever, headache) appeared at day 1 (70, 45%), followed at day 3 to 4 273 by chest pain (107, 68%) and shortness of breath (26, 17%). Electrocardiogram (ECG) was 274 abnormal for 68 (43%) patients with myocarditis and troponin was elevated for 41 (26%). The 275 most common drugs reported to treat these myocarditis reactions included non-steroidal anti-276 inflammatory drugs (NSAID) (23, 15%) and colchicine (22, 14%). Corticosteroid therapy was 277 infrequent (8, 5%). A total of 83 (53%) patients with reports of myocarditis were hospitalized, for 278 a median duration of 2.5 days. Figure 5 summarizes the typical patient management procedure 279 for a myocarditis following mRNA COVID-19 vaccine.

280

- 281
- 282
- 283

284 **Discussion**

285 In this global pharmacovigilance retrospective observational study, we report here the 286 largest case series to date on the clinical features of inflammatory heart reactions, myocarditis 287 and pericarditis, following COVID-19 mRNA vaccine immunization. These cases mostly 288 required hospitalization and some were life threatening, and occasionally fatal. Fatal cases 289 occurred in about 1% of the patients, mostly older. Although our analysis cannot assess real 290 incidence, these inflammatory heart reactions representing 31.8 per 10,000 of COVID-19 mRNA 291 vaccine reports appeared to be rare. Regarding myocarditis, our global data show that they were 292 highly likely to be reported in adolescents and young adults below 30 years old. Males has a high 293 disproportionate reporting risk compared to females.

294 Overall clinical features from these databases are also consistent with the experience 295 reported by the Israeli investigators. They have identified 110 myocarditis cases amongst their 5 million population who received 2 doses of the tozinameran vaccine.¹⁴ This translates to 296 297 approximately 1 in 50,000 vaccine recipients, noting however the rates in young males were 5 to 298 25 times higher than expected. The investigators also observed a higher rate of incidence 299 following the second dose, as well as 2 deaths in the cohort which may or may not be causally 300 related. This overall pattern is consistent with features of traditional viral myocarditis, which 301 occurs more commonly in younger male patients. Noteworthy, Israel's spontaneous reports are 302 not transmitted to VigiBase. Israel has been a leader in the current global mass immunization 303 effort, due to the achievements of the campaign, a larger proportion of young people have been

304 vaccinated compared to other countries using mRNA vaccines. The CDC reported that 305 myocarditis reactions after vaccination with tozinameran vaccine were reported by adolescents 306 aged 12–17 years to U.S. vaccine safety monitoring systems.³⁷

Myocarditis and pericarditis have been previously reported after vaccinations.⁸ The most well studied example is that following smallpox vaccine, which in the relatively heathy U.S. military personnel had an incidence of myocarditis of 1 in 12,819 individuals.³⁸ The complication rate was significantly decreased when the vaccine dose was subsequently reduced, suggesting a causal relationship, but it featured a live attenuated virus. Inflammatory cardiac reactions after inactivated virus vaccines such as influenza vaccines are also known to occur, but are generally considered as rare events, mainly occurring in young adults.⁸

314 Following the widespread adoption of community-based mitigation measures to reduce 315 the transmission of SARS-CoV-2, the percentage of other respiratory diseases, such as influenza infection, has declined to historically low levels.^{39,40} Therefore, we can hypothesize that the 316 317 background risk for myocarditis is probably lower than usual. In this present study, distribution 318 of myocarditis/pericarditis by sex and age was similar to previous cases described for other vaccines: mostly young adult males.⁸ Potential mechanisms for these observed reactions are 319 320 currently unknown, but several hypotheses may be considered. The first is that incidence appears 321 to be higher in situations related to higher immune reactivity (younger patient population, after 322 second dose, etc.). This may be related to greater adaptive immune response in younger 323 individuals, which in turn may lead to greater increases of CD4+ Th17+ cell populations, which 324 predisposes individuals to developing myocarditis. It will be interesting to see if the recently 325 reported microRNA diagnostic of Th17 activation in myocarditis is also positive in these patients.⁴¹ Second is the possibility that mRNA in these vaccines may enhance autoimmunity.⁴² 326 327 mRNA is known to be a self-adjuvant for innate immune responses, and this may help to explain

328 their immunogenicity, and may also trigger excessive immune responses in some individuals, 329 especially when there may be presence of a cross-reacting antigen. Optimization of mRNA dose 330 delivered is needed to elicit appropriate immune response while minimizing undesirable 331 inflammatory reactions, reassessing the dosing frequency and time interval between doses, as 332 well as optimization of all ingredients associated with the messenger RNA, in order to achieve 333 the most beneficial outcome of effective immunization with the least number of adverse effects to 334 all different population demographics. No previous or concomitant COVID-19 disease before 335 vaccination were reported in VAERS narratives. Some countries, such as France, recommend for 336 individuals with previous SARS-CoV-2 infection to delay vaccination from three to six months 337 after recovery, and to administer only one dose. Finally, with regards to COVID-19, it has been 338 hypothesized that myocarditis can occur due to direct cell invasion via the spike protein 339 interacting with the angiotensin-converting enzyme 2 (ACE2), which is widely expressed and prevalent in cardiomyocytes.^{43,44} However, in case of COVID-19 related myocarditis, SARS-340 341 CoV-2 has not been found in cardiomyocytes, but only in the remaining myocardium, thus the 342 cell injury was thought to be due to the generalized inflammatory response to COVID-19, part of which is Th1 activation.⁴⁵ Hence in COVID-19 mRNA vaccine associated myocarditis, it appears 343 344 unlikely that the translation of large amount of SARS-CoV-2 spike proteins through the vaccines 345 may also engage the ACE2 and related receptors and play a role in reaction onset.

346

This retrospective pharmacovigilance analysis has some limitations and strengths. VigiBase and VAERS are based on spontaneous reports. Anyone can submit a report, including parents and patients, which are analyzed and documented by national or regional pharmacovigilance centers. Spontaneous reports will likely feature under-reporting of total real world cases and variable data quality, all of which are inherent to any pharmacovigilance system.
 ⁴⁶

353 For instance, previous prospective study of the incidence of myocarditis/pericarditis following 354 smallpox and influenza vaccination suggested significant underestimation of true incidence of these complications with passive surveillance alone.⁴⁷ Hence, one major limitation of 355 356 spontaneous reporting is that it is not possible to assess incidence of inflammatory heart reactions 357 following COVID-19 vaccination and total number of cases is highly underestimated. However, 358 VigiBase, covering more than 90% of the world's population, provides a unique opportunity to 359 analyze rare adverse events at a global scale. Furthermore, although we cannot eliminate residual 360 confounders, disproportionality analysis on VigiBase has proven its value in detecting safety signal or increased risk of events.³⁴ Our analysis highlights an increased risk of myocarditis 361 362 reporting in young males. On one hand, myocarditis has suffered from a notoriety bias in relation 363 with media communication which has probably increase its reporting in May and June 2021 364 compared to other vaccine related events. On the other hand, because of an exceptionally high 365 number of reports with these new COVID-19 mRNA vaccines that are associated to an important 366 reactogenicity, non-cases reporting may be inflated as well, resulting in an underestimation of 367 this risk. Finally, it is not likely that study groups in our disproportionality analysis, based on 368 patient age and sex, may have been imbalanced in relation with these limitations. Sensitivity 369 analyses showing consistent results strengthen our findings. Hence, data from VigiBase and 370 VAERS reports should always be interpreted with caution, and consistency across datasets will be most important for validation of conclusions.⁴⁸ 371

372

373 We first report a global analysis on inflammatory cardiac reactions such as 374 myocarditis/pericarditis occurring after COVID-19 mRNA vaccine. Compared to hundreds of

375 millions of doses administered worldwide, these complications appeared to be rarely reported, 376 although most of them required hospitalization. Reporting risk of myocarditis is highly increased 377 in adolescents or young adults, and in males. Absolute risk may greatly increase with the 378 achievements of the mass immunization campaign and the enlargement of vaccination to young 379 adults. COVID-19 mRNA vaccine causality has been established by national authorities; further 380 data will be needed to analyze this safety signal. Meanwhile, recommendations should be 381 communicated to manage mass immunization in young adults and children, especially males. Some authors pledge for adapting the doses and number of doses needed.⁴⁹ Benefits of COVID-382 383 19 vaccine still significantly outweigh their risks, including these rare inflammatory heart 384 complications, given the current prevalence of SARS-CoV-2 infections in the world. As COVID-385 19 vaccine administration increases worldwide, clinicians and the public should be aware of the 386 features of these inflammatory heart reactions, and follow appropriate monitoring and treatment procedures as with other cases of myocarditis.⁵⁰ Maximal monitoring efforts by all relevant 387 388 national and international agencies are needed to unlock key parameters to optimize future 389 generations of vaccine platforms and dissemination to the general public resulting in maximum 390 benefit potential. Guidelines are needed to take this specific risk into account and to adapt 391 vaccination (dosage, timing and protocol) for younger people and males. In the future, as newer 392 formulations are being developed, such as for vaccine boosters, the dose and timing for the at-risk 393 cohort for cardiac complications should be considered to maximize the benefit to risk ratio.

394

396 Acknowledgments

VigiBase is a fully deidentified database maintained by the Uppsala Monitoring Center (UMC). The authors are indebted to the National Pharmacovigilance centres that contributed data. Information from VigiBase comes from a variety of sources, and the probability that the suspected adverse effect is drug-related is not the same in all cases. The information does not represent the opinion of the Uppsala Monitoring Center (UMC) or the World Health Organization and only reflects the authors' opinion.

403 According to VigiBase access rules, no specific ethical approval is needed. VigiBase access is 404 granted to national and regional pharmacovigilance centers such our teams.

405

406 Sources of funding: This work is supported in part by research grants from the Canadian
407 Institutes of Health Research, Heart & Stroke Foundation of Canada, Genome Canada, and
408 University of Ottawa of Heart Institute.

409

410 **Disclosures:** none

411

412 **Data availability**: aggregated data of spontaneous reports are available at 413 http://www.vigiaccess.org/.

414

415 **Author contributions**

AB, LC and PL designed the study. AB and LC drafted the article and performed data extraction
and statistical analysis. PL, MAK, TSK, GN, JR, MDD, MBVR, FS, JM and JMT critically
reviewed the article. All the authors approved the final version of the article.

420 **REFERENCES**

- Epelman S, Liu PP, Mann DL. Role of innate and adaptive immune mechanisms in cardiac
 injury and repair. *Nat Rev Immunol.* 2015;15:117–129.
- Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, Olsen E,
 Thiene G, Goodwin J, Gyarfas I, Martin I, Nordet P. Report of the 1995 World Health
 Organization/International Society and Federation of Cardiology Task Force on the
 Definition and Classification of cardiomyopathies. *Circulation*. 1996;93:841–842.
- Joy G, Artico J, Kurdi H, Seraphim A, Lau C, Thornton GD, Oliveira MF, Adam RD,
 Aziminia N, Menacho K, Chacko L, Brown JT, Patel RK, Shiwani H, Bhuva A, Augusto
 JB, Andiapen M, McKnight A, Noursadeghi M, Pierce I, Evain T, Captur G, Davies RH,
 Greenwood JP, Fontana M, Kellman P, Schelbert EB, Treibel TA, Manisty C, Moon JC,
 COVIDsortium Investigators. Prospective Case-Control Study of Cardiovascular
 Abnormalities 6 Months Following Mild COVID-19 in Healthcare Workers. JACC
 Cardiovasc Imaging. 2021;S1936-878X(21)00356–9.
- 434
 4. Daniels CJ, Rajpal S, Greenshields JT, Rosenthal GL, Chung EH, Terrin M, Jeudy J,
 435
 436
 436
 436
 437
 437
 437
 438
 438
 438
 439
 439
 439
 440
 440
 430
 434
 434
 435
 435
 436
 436
 437
 437
 438
 438
 439
 439
 439
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440</l
- Ma R, Wang Q, Meng D, Li K, Zhang Y. Immune checkpoint inhibitors-related myocarditis
 in patients with cancer: an analysis of international spontaneous reporting systems. *BMC Cancer*. 2021;21:38.
- Eckart RE, Love SS, Atwood JE, Arness MK, Cassimatis DC, Campbell CL, Boyd SY,
 Murphy JG, Swerdlow DL, Collins LC, Riddle JR, Tornberg DN, Grabenstein JD, Engler
 RJM, Department of Defense Smallpox Vaccination Clinical Evaluation Team. Incidence
 and follow-up of inflammatory cardiac complications after smallpox vaccination. *J Am Coll Cardiol.* 2004;44:201–205.
- Griffin JM, Woznica E, Gilotra NA, Nucifora FC. Clozapine-Associated Myocarditis: A
 Protocol for Monitoring Upon Clozapine Initiation and Recommendations for How to
 Conduct a Clozapine Rechallenge. *J Clin Psychopharmacol.* 2021;41:180–185.
- 8. Su JR, McNeil MM, Welsh KJ, Marquez PL, Ng C, Yan M, Cano MV. Myopericarditis
 after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990-2018. *Vaccine*.
 2021;39:839–845.
- 455 9. Mei R, Raschi E, Forcesi E, Diemberger I, De Ponti F, Poluzzi E. Myocarditis and 456 pericarditis after immunization: Gaining insights through the Vaccine Adverse Event 457 Reporting System. *Int J Cardiol*. 2018;273:183–186.

- Casey CG, Iskander JK, Roper MH, Mast EE, Wen X-J, Török TJ, Chapman LE, Swerdlow DL, Morgan J, Heffelfinger JD, Vitek C, Reef SE, Hasbrouck LM, Damon I, Neff L, Vellozzi C, McCauley M, Strikas RA, Mootrey G. Adverse events associated with smallpox vaccination in the United States, January-October 2003. *JAMA*. 2005;294:2734–2743.
- 462 11. Gatti M, Raschi E, Moretti U, Ardizzoni A, Poluzzi E, Diemberger I. Influenza Vaccination
 463 and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the
 464 Likelihood of Interaction through the Vaccine Adverse Event Reporting System and
 465 VigiBase. *Vaccines*. 2021;9:19.
- 466 12. Watkins K, Griffin G, Septaric K, Simon EL. Myocarditis after BNT162b2 vaccination in a
 467 healthy male. *Am J Emerg Med*. 2021;S0735-6757(21)00536–2.
- Purdy A, Ido F, Sterner S, Tesoriero E, Matthews T, Singh A. Myocarditis in COVID-19
 presenting with cardiogenic shock: a case series. *Eur Heart J Case Rep.* 2021;5:ytab028.
- 470 14. Montgomery J, Ryan M, Engler R, Hoffman D, McClenathan B, Collins L, Loran D, Hrncir
 471 D, Herring K, Platzer M, Adams N, Sanou A, Cooper LT. Myocarditis Following
 472 Immunization With mRNA COVID-19 Vaccines in Members of the US Military. *JAMA*473 *Cardiol*. 2021;
- Larson KF, Ammirati E, Adler ED, Cooper LT, Hong KN, Saponara G, Couri D, Cereda A,
 Procopio A, Cavalotti C, Oliva F, Sanna T, Ciconte VA, Onyango G, Holmes DR, Borgeson
 DD. Myocarditis After BNT162b2 and mRNA-1273 Vaccination. *Circulation*.
 2021;144:506–508.
- 478 16. Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA Vaccines. *Circulation*.
 479 2021;
- 480 17. Gargano JW, Wallace M, Hadler SC, Langley G, Su JR, Oster ME, Broder KR, Gee J,
 481 Weintraub E, Shimabukuro T, Scobie HM, Moulia D, Markowitz LE, Wharton M, McNally
 482 VV, Romero JR, Talbot HK, Lee GM, Daley MF, Oliver SE. Use of mRNA COVID-19
 483 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the
 484 Advisory Committee on Immunization Practices United States, June 2021. *MMWR Morb*485 *Mortal Wkly Rep.* 2021;70:977–982.
- 486 18. Jackson NAC, Kester KE, Casimiro D, Gurunathan S, DeRosa F. The promise of mRNA
 487 vaccines: a biotech and industrial perspective. *NPJ Vaccines*. 2020;5:11.
- Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T, COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med*. 2021;384:403–416.
- Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc
 G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina

- WV, Cooper D, Frenck RW, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan
 DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC, C4591001 Clinical Trial
 Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med.*2020;383:2603–2615.
- 500 21. CDC. COVID Data Tracker [Internet]. Cent. Dis. Control Prev. 2020 [cited 2021 May
 501 20];Available from: https://covid.cdc.gov/covid-data-tracker
- Soeiro T, Salvo F, Pariente A, Grandvuillemin A, Jonville-Béra A-P, Micallef J. Type I
 interferons as the potential mechanism linking mRNA COVID-19 vaccines to Bell's palsy.
 Therapie. 2021;76:365–367.
- Shimabukuro TT, Cole M, Su JR. Reports of Anaphylaxis After Receipt of mRNA COVIDVaccines in the US-December 14, 2020-January 18, 2021. *JAMA*. 2021;325:1101–1102.
- Renoud L, Khouri C, Revol B, Lepelley M, Perez J, Roustit M, Cracowski J-L. Association
 of Facial Paralysis With mRNA COVID-19 Vaccines: A Disproportionality Analysis Using
 the World Health Organization Pharmacovigilance Database. *JAMA Intern Med.* 2021;
- 510 25. Vogel G, Couzin-Frankel J. Israel reports link between rare cases of heart inflammation and
 511 COVID-19 vaccination in young men [Internet]. Sci. AAAS. 2021 [cited 2021 Jun
 512 6];Available from: https://www.sciencemag.org/news/2021/06/israel-reports-link-between513 rare-cases-heart-inflammation-and-covid-19-vaccination
- 514 26. Diaz GA, Parsons GT, Gering SK, Meier AR, Hutchinson IV, Robicsek A. Myocarditis and
 515 Pericarditis After Vaccination for COVID-19. *JAMA*. 2021;
- 516 27. COVID-19 vaccine benefits still outweigh risks, despite possible rare heart complications 517 [Internet]. Am. Heart [cited] 2021 May 28];Available Assoc. from: 518 https://newsroom.heart.org/news/covid-19-vaccine-benefits-still-outweigh-risks-despite-519 possible-rare-heart-complications
- PINHO AC. Comirnaty and Spikevax: possible link to very rare cases of myocarditis
 pericarditis [Internet]. Eur. Med. Agency. 2021 [cited 2021 Aug 11];Available from:
 https://www.ema.europa.eu/en/news/comirnaty-spikevax-possible-link-very-rare-cases myocarditis-pericarditis
- 29. Commissioner O of the. Coronavirus (COVID-19) Update: June 25, 2021 [Internet]. FDA.
 2021 [cited 2021 Aug 11];Available from: https://www.fda.gov/news-events/pressannouncements/coronavirus-covid-19-update-june-25-2021
- 527 30. Lindquist M. VigiBase, the WHO Global ICSR Database System: Basic Facts. Drug Inf J.
 528 2008;42:409–419.
- Shimabukuro TT, Nguyen M, Martin D, DeStefano F. Safety monitoring in the Vaccine
 Adverse Event Reporting System (VAERS). *Vaccine*. 2015;33:4398–4405.

- 32. Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, Haber P, Pless RP,
 Mootrey G, Ellenberg SS, Braun MM, Chen RT. Surveillance for safety after immunization:
 Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001. *Morb Mortal Wkly Rep Surveill Summ Wash DC 2002*. 2003;52:1–24.
- 535 33. Toulouse E, Lafont B, Granier S, Mcgurk G, Bazin J-E. French legal approach to patient
 536 consent in clinical research. *Anaesth Crit Care Pain Med*. 2020;39:883–885.
- 34. Montastruc J-L, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the
 disproportionality analysis for identification of adverse drug reactions in a
 pharmacovigilance database. *Br J Clin Pharmacol.* 2011;72:905–908.
- 540 35. Faillie J-L. Case-non-case studies: Principle, methods, bias and interpretation. *Therapie*.
 541 2019;74:225–232.
- 542 36. Khouri C, Petit C, Tod M, Lepelley M, Revol B, Roustit M, Cracowski J-L. Adverse drug
 543 reaction risks obtained from meta-analyses and pharmacovigilance disproportionality
 544 analyses are correlated in most cases. *J Clin Epidemiol*. 2021;134:14–21.
- 37. Hause AM, Gee J, Baggs J, Abara WE, Marquez P, Thompson D, Su JR, Licata C,
 Rosenblum HG, Myers TR, Shimabukuro TT, Shay DK. COVID-19 Vaccine Safety in
 Adolescents Aged 12-17 Years United States, December 14, 2020-July 16, 2021. MMWR
 Morb Mortal Wkly Rep. 2021;70:1053–1058.
- 38. Halsell JS, Riddle JR, Atwood JE, Gardner P, Shope R, Poland GA, Gray GC, Ostroff S,
 Eckart RE, Hospenthal DR, Gibson RL, Grabenstein JD, Arness MK, Tornberg DN,
 Department of Defense Smallpox Vaccination Clinical Evaluation Team. Myopericarditis
 following smallpox vaccination among vaccinia-naive US military personnel. *JAMA*.
 2003;289:3283–3289.
- 39. Olsen SJ, Azziz-Baumgartner E, Budd AP, Brammer L, Sullivan S, Pineda RF, Cohen C,
 Fry AM. Decreased Influenza Activity During the COVID-19 Pandemic United States,
 Australia, Chile, and South Africa, 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69:1305–
 1309.
- 40. Jones N. How COVID-19 is changing the cold and flu season. *Nature*. 2020;588:388–390.
- 559 41. Blanco-Domínguez R, Sánchez-Díaz R, de la Fuente H, Jiménez-Borreguero LJ, Matesanz-560 Marín A, Relaño M, Jiménez-Alejandre R, Linillos-Pradillo B, Tsilingiri K, Martín-561 Mariscal ML, Alonso-Herranz L, Moreno G, Martín-Asenjo R, García-Guimaraes MM, Bruno KA, Dauden E, González-Álvaro I, Villar-Guimerans LM, Martínez-León A, 562 563 Salvador-Garicano AM, Michelhaugh SA, Ibrahim NE, Januzzi JL, Kottwitz J, Iliceto S, 564 Plebani M, Basso C, Baritussio A, Seguso M, Marcolongo R, Ricote M, Fairweather D, 565 Bueno H, Fernández-Friera L, Alfonso F, Caforio ALP, Pascual-Figal DA, Heidecker B, Lüscher TF, Das S, Fuster V, Ibáñez B, Sánchez-Madrid F, Martín P. A Novel Circulating 566 567 MicroRNA for the Detection of Acute Myocarditis. N Engl J Med. 2021;384:2014–2027.

- Liu PP, Blet A, Smyth D, Li H. The Science Underlying COVID-19: Implications for the
 Cardiovascular System. *Circulation*. 2020;142:68–78.
- 570 43. Siripanthong B, Nazarian S, Muser D, Deo R, Santangeli P, Khanji MY, Cooper LT, Chahal
 571 CAA. Recognizing COVID-19-related myocarditis: The possible pathophysiology and
 572 proposed guideline for diagnosis and management. *Heart Rhythm.* 2020;17:1463–1471.
- 44. Hikmet F, Méar L, Edvinsson Å, Micke P, Uhlén M, Lindskog C. The protein expression
 profile of ACE2 in human tissues. *Mol Syst Biol.* 2020;16:e9610.
- 575 45. Mele D, Flamigni F, Rapezzi C, Ferrari R. Myocarditis in COVID-19 patients: current
 576 problems. *Intern Emerg Med*. 2021;16:1123–1129.
- 46. Navar AM, McNally E, Yancy CW, O'Gara PT, Bonow RO. Temporal Associations
 Between Immunization With the COVID-19 mRNA Vaccines and Myocarditis: The
 Vaccine Safety Surveillance System Is Working. *JAMA Cardiol*. 2021;
- 580 47. Engler RJM, Nelson MR, Collins LC, Spooner C, Hemann BA, Gibbs BT, Atwood JE,
 581 Howard RS, Chang AS, Cruser DL, Gates DG, Vernalis MN, Lengkeek MS, McClenathan
 582 BM, Jaffe AS, Cooper LT, Black S, Carlson C, Wilson C, Davis RL. A prospective study of
 583 the incidence of myocarditis/pericarditis and new onset cardiac symptoms following
 584 smallpox and influenza vaccination. *PloS One*. 2015;10:e0118283.
- Loughlin AM, Marchant CD, Adams W, Barnett E, Baxter R, Black S, Casey C, Dekker C,
 Edwards KM, Klein J, Klein NP, LaRussa P, Sparks R, Jakob K. Causality assessment of
 adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). *Vaccine*. 2012;30:7253–7259.
- 58949.Harlan M. Krumholz MD. Myocarditis After mRNA COVID-19 Vaccine. NEJM J Watch590[Internet].2021[cited 2021 Aug 12];2021.Available from:591https://www.jwatch.org/NA53825/2021/07/20/myocarditis-after-mrna-covid-19-vaccine
- 592 50. Ammirati E, Frigerio M, Adler ED, Basso C, Birnie DH, Brambatti M, Friedrich MG,
 593 Klingel K, Lehtonen J, Moslehi JJ, Pedrotti P, Rimoldi OE, Schultheiss H-P, Tschöpe C,
 594 Cooper LT, Camici PG. Management of Acute Myocarditis and Chronic Inflammatory
 595 Cardiomyopathy: An Expert Consensus Document. *Circ Heart Fail*. 2020;13:e007405.

597 FIGURE TITLES AND LEGENDS

599	Figure 1. Clinical and demographic features concerning inflammatory heart reaction after
600	mRNA COVID-19 vaccines
601	The data shown refer to VigiBase data.
602	(A) Sex distribution according to reaction type (myocarditis and pericarditis). (B) Reaction type
603	(Myocarditis or Pericarditis) distribution according to age. Myocarditis presented most frequently
604	in young people of 18-29 years old, whereas pericarditis presented most frequently in people over
605	65 years old. (C) Sex distribution according to reaction type and age.
606	
607	Figure 2. Reported cases of myocarditis and number of people vaccinated among 12-17 and
608	18-29 year old in the U.S
609	Myocarditis originating from the U.S. were mainly reported after May 2021.
610	
611	Figure 3. Time to onset and main symptoms reported by type of reaction
612	Time to onset was earlier for myocarditis. Most frequent symptoms reported were chest pain,
613	elevated troponin and systemic reactogenicity.
614	SOB, shortness of breath
615	

616 Figure 4. Comparison of reports of inflammatory cardiac disorders in COVID-19 mRNA

617 vaccine recipients according sex and age within the WHO global safety database

618

619 ROR, Reporting odds-ratio; 95% CI, 95% confidence interval.

620 Case-non-case approach is similar to case-control method but for the purposes of 621 pharmacovigilance studies. Disproportionality in adverse drug reaction reporting between groups 622 is expressed using reporting odds ratios (ROR) and their 95% confidence interval (95% CI). ROR 623 is a ratio similar in concept to the odds ratio in case-control studies and corresponds to the 624 exposure odds among reported cases of inflammatory cardiac disorders over the exposure odds 625 among reported non-cases. An ROR over 1.0 suggests that inflammatory cardiac disorders are 626 more frequently reported in COVID-19 mRNA vaccine recipients specific group compared with 627 control group. We performed the main analysis and a secondary analysis stratified to age groups.

* Inflammatory cardiac disorders cases were individual case safety reports containing the terms
myocarditis or pericarditis as a reported preferred term according to the Medical Dictionary for
Regulatory Activities (MedDRA, <u>https://www.meddra.org/</u>). Cases of myopericarditis have been
considered as myocarditis.

632 ** Non cases were reports containing any other reaction.

633

634 Figure 5. Management of a typical vaccine related myocarditis patient

The typical journey of patient experienced a myocarditis following an mRNACOVID-19 vaccine is described. Starting at day 0 after receiving 1st or 2nd dose of vaccine. Appearance of systemic reactogenicity symptoms at day 1, followed by chest pain and shortness of breath (SOB) at day 3, leading to consultation at the Emergency Room (ER), and hospitalization for a median of 2 days.

- 639 SOB, shortness of breath; EKG, electrocardiogram; CT, computed tomography; NSAID, non-
- 640 steroidal anti-inflammatory drug.
- 641
- 642 Supplemental Figure 1. Date of reporting and reaction of inflammatory heart reaction cases
- 643 in VigiBase.
- 644

Reporting characteristics	Tozinameran	Elasomeran	Overall
	vaccine	vaccine	(2277)
Continent of reporting	(n=1655)	(n=622)	(n=2277)
- North America	942 (56.9%)	502 (80.7%)	1444 (63.4%)
- Europa	676 (40.8%)	120 (19.3%)	796 (35.0%)
- Oceania	31 (1.9%)	120 (19.5%)	31 (1.4%)
- Latin America	5 (0.3%)	-	51(1.4%) 5(0.2%)
- Latin America - Africa	· · · ·	-	· · ·
Type of reporter	1 (0.1%)	-	1 (0.1%)
- Physician	383 (23.1%)	75 (12.1%)	458 (20.1%)
- Pharmacist	35 (2.1%)	9 (1.4%)	438 (20.1%) 44 (1.9%)
		· · ·	· · ·
- Other health professional	46 (2.8%)	2 (0.3%)	48 (2.1%)
- Consumer	234 (14.1%)	34 (5.5%)	268 (11.8%)
- Unknown	957 (57.8%)	502 (80.7%)	1459 (64.1%)
Sex – male (%)	1108 (66.9%)	447 (71.9%)	1555 (68.3%)
Age – years	33 (19-55)	31 (22-52)	33 (21-54)
Age – ranges			
- 12 - 17 years	291 (17.6%)	3 (0.5%)	294 (12.9%)
- 18 - 29 years	425 (25.7%)	279 (44.9%)	704 (30.9%)
-30 - 39 years	234 (14.1%)	103 (16.6%)	337 (14.8%)
- 40 - 49 years	171 (10.3%)	64 (10.3%)	235 (10.3%)
- 50 - 59 years	173 (10.5%)	50 (8.0%)	223 (9.8%)
- 60 - 64 years	74 (4.5%)	30 (4.8%)	104 (4.6%)
- 65+	240 (14.5%)	77 (12.4%)	317 (13.9%)
- Unknown	47 (2.8%)	16 (2.6%)	63 (2.8%)
Type of heart inflammatory injury			
Myocarditis	905 (54.7%)	336 (54.0%)	1241 (54.5%)
- Including requiring hospitalization	573 (63.3%)	223 (66.4%)	796 (64.1%)
- Including life threatening condition	150 (16.6%)	69 (20.5%)	219 (17.6%)
- Including fatal outcome	11 (1.2%)	4 (1.2%)	15 (1.2%)
		220 (25 00())	
• Pericarditis	621 (37.5%)	230 (37.0%)	851 (37.4%)
- Including requiring hospitalization	287 (46.2%)	104 (45.2%)	391 (45.9%) 101 (11.9%)
 Including life threatening condition Including fatal outcome 	59 (9.5%) 3 (0.5%)	42 (18.3%) 2 (0.9%)	101 (11.9%) 5 (0.6%)
- Including Jului bulcome	5 (0.570)	2 (0.970)	5 (0.070)
• Myopericarditis	115 (6.9%)	52 (8.4%)	167 (7.3%)
- Including requiring hospitalization	71 (61.7%)	38 (73.1%)	107 (7.3%)
- Including life threatening condition	21 (18.3%)	8 (15.4%)	29 (17.4%)
- Including fatal outcome	1 (0.9%)	1 (1.9%)	2 (1.2%)
Pleuropericarditis	14 (0.8%)	4 (0.6%)	18 (0.8%)
- Including requiring hospitalization	10 (71.4%)	2 (50.0%)	12 (66.7%)
- Including life threatening condition	2 (14.3%)	1 (25.0%)	3 (16.7%)
- Including fatal outcome	-		
Time to onset – days			
• Myocarditis	3 [2-7]	3 [2-4]	3 [2-6]
• Pericarditis	8 [3-20]	10 [4-33]	8 [3-21]
 Myopericarditis 	4 [2-14]	3 [2-12]	4 [2-14]
Pleuropericarditis	8 [3-23]	6 [2-13]	7 [3-19]
Cases with other suspected reported drug***	155 (9.4%)	45 (7.2%)	200 (8.7%)

Table 1. Characteristics of acute inflammatory heart cases reported with COVID-19mRNA vaccines within the WHO global safety database

Month of reporting			
- January	21 (1.3%)	-	21 (0.9%)
- February	63 (3.8%)	33 (5.3%)	96 (4.2%)
- March	79 (4.8%)	27 (4.3%)	106 (4.7%)
- April	58 (3.5%)	22 (3.5%)	80 (3.5%)
- May	369 (22.3%)	118 (19.0%)	487 (21.4%)
- June	1065 (64.4%)	422 (67.8%)	1487 (65.3%)

Data are presented as N (%) or median (IQR)

Table 2. Characteristics of acute inflammatory heart cases reported with COVID-19mRNA vaccines within the VAERS classified by the type of reaction


Reporting characteristics	Myocarditis	Pericarditis	Overall
(%) or median [IR]	(n=157)	(n=122)	(n=279)
Vaccine type	00 (570()	72 ((00))	117 (100)
- Tozinameran	89 (57%)	73 (60%)	117 (42%)
- Elasomeran	68 (43%)	49 (40%)	162 (58%)
Sex	114 (500)		100 (650)
- Male	114 (73%)	68 (55%)	182 (65%)
- Female	38 (24%)	52 (43%)	90 (32%)
- Unknown	5 (3%)	2 (2%)	7 (3%)
Age – ranges			
- 12 - 17 years	7 (4%)	0 (0%)	7 (3%)
- 18 - 29 years	75 (48%)	17 (14%)	92 (33%)
-30 - 39 years	28 (18%)	22 (18%)	50 (18%)
- 40 - 49 years	24 (15%)	11 (9%)	35 (13%)
- 50 - 59 years	8 (5%)	21 (17%)	29 (10%)
- 60 - 64 years	3 (2%)	7 (6%)	10 (4%)
- 65+	7 (4%)	38 (31%)	45 (16%)
- Unknown	5 (3%)	6 (5%)	11 (4%)
COVID-19 prior to vaccination	10 (6%)	8 (7%)	18 (6%)
After 1 st dose	22 (14%)	29 (24%)	52 (19%)
- Covid prior vaccination			13 (25%)
 No Covid prior vaccination 			15 (29%)
- Unknown			24 (46%)
After 2 nd dose	56 (36%)	30 (25%)	87 (31%)
 Covid prior vaccination 			2 (2%)
 No Covid prior vaccination 			34 (39%)
- Unknown			51 (59%)
After unspecified dose	79 (50%)	63 (51%)	140 (50%)
- Covid prior vaccination			3 (2%)
- No Covid prior vaccination			12 (9%)
- Unknown			125 (89%)
Onset of the first symptoms – days	3 [2-4]	3 [2-9]	3 [2-5]
Symptoms			
- Systemic reactogenicity signs	70 (45%)	37 (30%)	108 (39%)
- Chest Pain	107 (68%)	79 (65%)	187 (67%)
- Shortness of breath	25 (16%)	31 (25%)	57 (20%)
EKG		. ,	
- Abnormal	67 (43%)	41 (34%)	110 (39%)
- ST elevation	41 (26%)	13 (11%)	54 (19%)
- Supraventricular arrhythmia	3 (2%)	13 (11%)	16 (6%)
Elevated Troponin	99 (63%)	19 (16%)	120 (43%)
Trans Thoracic Echocardiography			
- Normal	22 (14%)	7 (6%)	29 (10%)
- Decreased LVEF	14 (9%)	4 (3%)	19 (7%)
CMR consistent with diagnosis	29 (18%)	1 (1%)	30 (11%)
Complications	_> (10/0)	. (1/0)	55 (11/0)
- CS or AHF	9 (6%)	1 (1%)	10 (4%)

- Cardiac arrest	2 (1%) 0 (0%)	0(0%)	2 (1%) 8 (3%)
- Tamponade Treatment	0 (0%)	8 (7%)	8 (3%)
- NSAID	23 (15%)	0 (0%)	43 (15%)
- Colchicine	22 (14%)	22 (18%)	44 (16%)
- Corticosteroids	8 (5%)	3 (2%)	12 (4%)
Hospitalization	83 (53%)	36 (30%)	121 (43%)
Length of hospital stay – days	2.5 [1-3]	2 [1-4]	2 [1-3]

Data are presented as N (%) or median (IQR)

Data extracted from VAERS up to May 21st 2021.

AHF, Acute Heart Failure; CMR, Cardiac magnetic resonance ; CS, Cardiogenic Shock; EKG, electrocardiogram; LVEF, Left ventricular ejection fraction; NSAID, non-steroidal anti-inflammatory drug.



M yocarditis

Pericarditis










Figure 1.




Figure 2.






Figure 3.



Pericarditis main symptoms


	Myocarditis cases*	Non cases**	ROR (95% CI)
Myocarditis – C	Overall analysis		
Male	1,049	171,495	9.4 (8.3-10.6)
Female	322	493,696	1 (Reference)
	• 40		
12-17 years	249	11,265	22.3 (19.2-25.9)
18-29 year	557	84,576	6.6 (5.9-7.5)
\geq 30 years	565	569,350	1 (Reference)
Myocarditis – A	analysis according to p	oatient age	1
Male			
12-17 years	225	4,940	18.5 (15.6-21.9)
18-29 year	464	20,111	9.4 (8.2-10.8)
\geq 30 years	360	146,444	1 (Reference)
Female			
12-17 years	24	6,325	7.8 (5.1-12.0)
18-29 years	93	64,465	3.0 (2.3-3.8)
\geq 30 years	205	422,906	1 (Reference)
Myocarditis – A	analysis according to p	oatient sex	
12-17 years			
Male	225	4,940	12.0 (7.9-18.3)
Female	24	6,325	1 (Reference)
18-29 years			
Male	464	20,111	16.0 (12.8-20.0)
Female	93	64,465	1 (Reference)
\geq 30 years			
Male	360	146,444	5.1 (4.3-6.0)
Female	205	422,906	1 (Reference)
remate	203	422,900	i (Reference)



Reporting Odds-Ratio

Figure 4.A

	Pericarditis cases*	Non cases**	ROR (95% CI)
Pericarditis – Over	all analysis		, , ,
Male	459	172,085	3.7 (3.2-4.2)
Female	360	493,658	1 (Reference)
12-17 years	45	11,469	3.5 (2.6-4.8)
18-29 year	145	84,988	1.5 (1.2-1.8)
\geq 30 years	629	569,286	1 (Reference)
Pericarditis – Anal	ysis according to p	atient age	
Male			
12-17 years	41	5,124	3.7 (2.6-5.1)
18-29 year	104	20,471	2.4 (1.9-3.0)
\geq 30 years	314	146,490	1 (Reference)
Female			
12-17 years	4	6,345	0.8 (0.3-2.3)
18-29 years	41	64,517	0.9 (0.6-1.2)
\geq 30 years	315	422,796	1 (Reference)
Pericarditis – Anal	ysis according to p	oatient sex	-
12-17 years			
Male	41	5,124	12.7 (4.5-35.5)
Female	4	6,345	1 (Reference)
18-29 years			
Male	104	20,471	8.0 (5.6-11.5)
Female	41	64,517	1 (Reference)
\geq 30 years			
Male	314	146,490	2.9 (2.5-3.4)
Female	315	422,796	1 (Reference)






Figure 4.B

Management of a typical vaccine related myocarditis patient

